| Drug General Information |
| Drug ID |
D0L4TM
|
| Former ID |
DNC012004
|
| Drug Name |
2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H16N2O
|
| Canonical SMILES |
C1=CC=C(C=C1)CCCN2C(=O)C3=CC=CC=C3N2
|
| InChI |
1S/C16H16N2O/c19-16-14-10-4-5-11-15(14)17-18(16)12-6-9-13-7-2-1-3-8-13/h1-5,7-8,10-11,17H,6,9,12H2
|
| InChIKey |
ZTUNGCGUHQENHO-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Prostaglandin G/H synthase 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Prostaglandin G/H synthase 1 |
Target Info |
Inhibitor |
[1]
|
| Arachidonate 5-lipoxygenase |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Aspirin-triggered lipoxin biosynthesis
|
|
Aspirin triggered resolvin D biosynthesis
|
|
C20 prostanoid biosynthesis
|
|
Aspirin triggered resolvin E biosynthesisPWY66-374:C20 prostanoid biosynthesisPWY66-393:Aspirin-triggered lipoxin biosynthesis
|
|
Resolvin D biosynthesis
|
|
Leukotriene biosynthesis
|
|
Lipoxin biosynthesis
|
|
Aspirin triggered resolvin E biosynthesis
|
|
KEGG Pathway
|
Arachidonic acid metabolism
|
|
Metabolic pathways
|
|
NF-kappa B signaling pathway
|
|
VEGF signaling pathway
|
|
TNF signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Serotonergic synapse
|
|
Ovarian steroidogenesis
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Leishmaniasis
|
|
Pathways in cancer
|
|
Chemical carcinogenesis
|
|
MicroRNAs in cancer
|
|
Small cell lung cancerhsa00590:Arachidonic acid metabolism
|
|
Platelet activation
|
|
Serotonergic synapsehsa00590:Arachidonic acid metabolism
|
|
Toxoplasmosis
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
IL5 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Endothelin signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Toll receptor signaling pathway
|
|
CCKR signaling map STP00031:Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Pathway Interaction Database
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
S1P1 pathway
|
|
C-MYB transcription factor network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
PathWhiz Pathway
|
Arachidonic Acid MetabolismPW000044:Arachidonic Acid MetabolismPW000044:Arachidonic Acid Metabolism
|
|
WikiPathways
|
Prostaglandin Synthesis and Regulation
|
|
Arachidonic acid metabolism
|
|
Aryl Hydrocarbon Receptor
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Eicosanoid Synthesis
|
|
Selenium Micronutrient NetworkWP98:Prostaglandin Synthesis and Regulation
|
|
Phase 1 - Functionalization of compounds
|
|
Selenium Micronutrient NetworkWP2877:Vitamin D Receptor Pathway
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | J Med Chem. 1991 Mar;34(3):1028-36.Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. |
|---|
